03737.HK
Zhongzhi Pharmaceutical Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 0.74
+5.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.7B | 1.7B | 2.2B | 2.0B | 1.8B |
| Cost of Revenue | 1.6B | 797.2M | 926.4M | 831.7M | 758.6M |
| Gross Profit | 2.0B | 940.3M | 1.3B | 1.2B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 96.6M | 41.5M | 57.0M | 50.0M | 46.4M |
| SG&A Expense | 1.9B | 893.9M | 1.1B | 994.8M | 914.6M |
| General & Admin Expense | 194.8M | 100.2M | 105.7M | 106.7M | 104.7M |
| Selling & Marketing Expense | 1.7B | 787.4M | 988.7M | 888.2M | 809.1M |
| Other Expenses | — | — | (18.9M) | (25.5M) | — |
| Total Operating Expenses | 2.0B | 935.3M | 1.1B | 1.0B | 960.9M |
| Cost and Expenses | 3.6B | 1.7B | 2.1B | 1.9B | 1.7B |
| Operating Income (EBIT) | 54.8M | 4.9M | 129.8M | 169.8M | 106.4M |
| Non-Operating | |||||
| Interest Income | 5.8M | 2.9M | 5.1M | 7.0M | 3.9M |
| Interest Expense | 3.3M | 5.2M | 7.0M | 7.9M | 6.6M |
| Net Interest Income | (3.6M) | (2.3M) | (1.9M) | (883.0K) | (2.7M) |
| Other Non-Op Income/Expense | 19.6M | 14.1M | 17.1M | 37.8M | 24.2M |
| Non-Operating Income (excl Interest) | 22.3M | 6.6M | 17.4M | (16.6M) | 2.9M |
| EBT (Pre-Tax Income) | 74.4M | 19.0M | 146.9M | 207.6M | 130.7M |
| Income Tax Expense | 52.2M | 1.3M | 50.8M | 43.4M | 23.7M |
| Bottom Line | |||||
| Net Income | 38.2M | 17.3M | 95.2M | 162.8M | 106.4M |
| Earnings from Cont. Ops | 22.2M | 17.7M | 96.1M | 164.1M | 106.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 38.2M | 17.3M | 95.2M | 162.8M | 106.4M |
| Per Share | |||||
| Basic EPS | HK$0.04 | HK$0.02 | HK$0.11 | HK$0.19 | HK$0.13 |
| Diluted EPS | HK$0.04 | HK$0.02 | HK$0.11 | HK$0.19 | HK$0.13 |
| Revenue Per Share | HK$4.33 | HK$2.11 | HK$2.62 | HK$2.42 | HK$2.16 |
| Shares | |||||
| Basic Shares Outstanding | 843.8M | 823.4M | 845.4M | 847.0M | 847.0M |
| Diluted Shares Outstanding | 843.7M | 823.4M | 845.4M | 847.0M | 847.0M |
| Profitability Metrics | |||||
| EBITDA | 142.2M | 55.3M | 170.4M | 317.5M | 153.9M |
| D&A | 109.7M | 57.0M | 50.9M | 102.1M | 50.4M |
| EBIT | 32.5M | (1.7M) | 119.5M | 215.4M | 103.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026